Saturday 17 October 2026 Export RMTI’s income statement to Excel — free account

Rockwell Medical, Inc.

RMTI Healthcare Drug Manufacturers Specialty & Generic

Rockwell Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $69.3 million, down 31.8% from fiscal 2024. In the quarter to June 2026, revenue grew 10.6%, EPS grew 32.0%, free cash flow fell 12.9% and total debt fell 1.73%, each against the same quarter a year earlier.

7.43 0.55 −6.89%

Follow RMTI

Alert me

Market cap: $32.2M
P/E: 0.0×
Fwd P/E: −7.4×
Dividend yield: —
F-score: 3/9
Altman Z: −7.44
Beneish M: −2.80
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.02

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	—	2	—	—	—	—	—	—	—	—	1

Insider Ownership 14.87%

Capital & Financial Ratios $m

Market Cap 32.16

Revenue 69.39

Net Income (5.08)

Free Cash Flow 1.72

Net Debt (15.69)

Current Ratio 3.25

Debt/Equity 0.26

P/E ratio 0.00

Fwd P/E (7.38)

P/S ratio 0.42

P/B ratio 0.84

Past 5Y EPS Growth —

This Y EPS Growth 32.67%

Next Y EPS Growth 79.70%

Next Y revenue growth 4.45%

Next 5Y EPS Growth 48.37%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 15.26%

10-year low 10-year high

P/B against its own 10 years 3.92%

10-year low 10-year high

EV/Sales against its own 10 years 7.20%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	11	22	25	25
Receivables	11	8	8	8
Inventory	6	6	3	3
Other	—	—	—	—
	29	37	38	36

	2023	2024	2025	Q'26
Payables	5	3	2	3
ST’ Debt	—	—	—	2
Other	0	0	0	0
	17	14	10	11

Compound Annual Growth %

	10y	5y	3y
Sales	2.27%	2.17%	(1.65%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(5.08%)	1.59%	37.89%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	17	18	—	—	—
’25	19	16	16	18	69
’24	23	26	28	25	101
’23	20	18	24	22	84
’22	16	19	19	19	73
’21	15	15	16	15	62
’20	16	16	15	15	62

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	2	—	—	—
’25	(3)	2	(1)	2	(1)
’24	(2)	1	4	1	4
’23	(4)	(2)	(4)	0	(9)
’22	(10)	(6)	(1)	0	(17)
’21	(12)	(5)	(7)	(9)	(34)
’20	(7)	(10)	(5)	(9)	(30)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	1	—	—	—
’25	(4)	2	(2)	2	(1)
’24	(3)	1	4	0	3
’23	(4)	(2)	(4)	0	(10)
’22	(10)	(6)	(1)	0	(17)
’21	(13)	(5)	(7)	(9)	(34)
’20	(7)	(10)	(6)	(9)	(31)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.40)	(0.34)	—	—	—
’25	(0.40)	(0.50)	(0.50)	(0.10)	(1.50)
’24	(0.60)	0.10	0.50	(0.20)	(0.15)
’23	(1.00)	(1.80)	(0.70)	(0.50)	(3.60)
’22	(8.40)	(4.28)	(2.27)	(2.00)	(13.06)
’21	(8.80)	(9.90)	(8.80)	(10.47)	(38.32)
’20	(13.20)	(11.00)	(11.00)	(9.90)	(45.10)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	390.50	556.60	240.90	199.10	91.30	37.40	8.40	10.00	11.60	7.80	Analyst estimates 2026–2028 Powerpack
	High	1,163.80	987.80	761.20	756.80	423.50	217.80	71.50	62.40	51.50	24.10
People
People	Employees	300	300	269	299	300	300	253	237	244	157
	Revenue/emp, $m	0.18	0.19	0.24	0.21	0.21	0.21	0.29	0.35	0.42	0.44
Income, $m
Income, $m	Revenue	53	57	63	61	62	62	73	84	101	69
	Gross margin, %	12.67	6.46	(2.50)	4.63	4.38	(3.91)	5.60	10.41	17.23	16.89
	EBT	(19)	(26)	(32)	(34)	(31)	(33)	(19)	(8)	0	(5)
	EBT margin, %	(36.41)	(45.24)	(50.68)	(55.67)	(49.66)	(52.76)	(25.65)	(10.09)	(0.47)	(7.67)
	Net income	(20)	(26)	(32)	(34)	(31)	(33)	(19)	(8)	0	(5)
	Depreciation	1	1	1	3	3	3	3	5	3	3
Per share, $
Per share, $	Revenue	115.68	123.44	132.00	110.70	90.48	72.64	50.90	35.85	32.68	19.25
	Earnings	(42.90)	(56.11)	(67.11)	(61.61)	(45.10)	(38.33)	(13.06)	(3.60)	(0.15)	(1.50)
	Cash flow	(27.04)	(45.48)	(42.52)	(49.21)	(43.12)	(39.33)	(11.83)	(4.04)	1.35	(0.18)
	Capex	(0.77)	(3.62)	(1.55)	(1.06)	(1.52)	(0.61)	(0.20)	(0.12)	(0.33)	(0.15)
	Free cash flow	(27.80)	(49.11)	(44.07)	(50.27)	(44.64)	(39.94)	(12.03)	(4.16)	1.03	(0.33)
	Book value	114.97	70.90	56.80	36.69	49.71	2.97	9.86	9.13	10.49	10.28
	Shares, m	0	0	0	1	1	1	1	2	3	4
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	6.12	5.03	1.88	2.42	1.23	0.62	0.20	0.52	0.62	0.43
	P/B	6.16	8.75	4.38	7.32	2.24	15.17	1.04	2.04	1.94	0.81
	EV/Sales	5.26	4.66	1.54	2.07	0.64	0.59	0.06	0.57	0.56	0.28
	EV/FCF	(18.09)	(10.47)	(4.10)	(4.15)	(1.19)	(1.00)	(0.23)	(3.87)	114.52	(5.04)
Cash, $m
Cash, $m	Operating cash flow	(12)	(21)	(20)	(27)	(30)	(34)	(17)	(9)	4	(1)
	Capex	0	(2)	(1)	(1)	(1)	(1)	0	0	(1)	(1)
	Free cash flow	(13)	(23)	(21)	(28)	(31)	(34)	(17)	(10)	3	(1)
Balance, $m
Balance, $m	Working capital	68	40	34	25	57	14	18	12	23	29
	Total debt	—	—	—	4	22	21	11	10	9	9
	Net debt	(58)	(33)	(34)	(22)	(37)	(2)	(10)	(1)	(12)	(16)
	Shareholders’ equity	53	33	27	20	34	3	14	21	33	37
Returns, %
Returns, %	ROA	(23.16)	(36.53)	(57.71)	(70.46)	(50.61)	(51.73)	(39.24)	(17.08)	(0.86)	(9.13)
	ROIC	0.00	0.00	0.00	0.00	0.00	(2,796.46)	(268.77)	(20.64)	1.86	(13.89)
	ROE	(34.36)	(60.37)	(106.75)	(143.40)	(113.38)	(178.04)	(224.49)	(47.68)	(1.78)	(15.28)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ZYBT Zhengye Biotechnology Holding Limited	$44.6M	—	—	—	—	−69.31% (below 0%: shrinking)	—	—	Compare
SCYX SCYNEXIS, Inc.	$38.9M	— (loss-making)	— (loss-making)	−8.56% (below 0%: shrinking)	n/m	−98.60% (below 0%: shrinking)	100.00%	(3,308.51%)	Compare
IXHL Incannex Healthcare Inc.	$36.1M	— (loss-making)	— (loss-making)	−92.31% (below 0%: shrinking)	n/m	+327.73% (above 0%: growing)	100.00%	0.00%	Compare
RMTI Rockwell Medical, Inc.	$32.2M	— (loss-making)	— (loss-making)	+10.63% (above 0%: growing)	n/m	−12.92% (below 0%: shrinking)	18.24%	(5.97%)
CPHI China Pharma Holdings, Inc.	$31.3M	— (loss-making)	— (loss-making)	−7.56% (below 0%: shrinking)	n/m	−113.57% (below 0%: shrinking)	8.82%	(150.99%)	Compare
SHPH Shuttle Pharmaceuticals Holdings, Inc.	$26.5M	0.2×	—	—	n/m	+82.01% (above 0%: growing)	0.00%	0.00%	Compare
TXMD TherapeuticsMD, Inc.	$22.3M	— (loss-making)	18.9×	−8.72% (below 0%: shrinking)	−80.00% (below 0%: shrinking)	+104.46% (above 0%: growing)	100.00%	(93.90%)	Compare
AYTU Aytu BioPharma, Inc.	$21.8M	— (loss-making)	— (loss-making)	+6.42% (above 0%: growing)	n/m	+57.72% (above 0%: growing)	64.63%	(4.82%)	Compare
UPC Universe Pharmaceuticals INC	$20.9M	— (loss-making)	4.1×	−23.98% (below 0%: shrinking)	−110.15% (below 0%: shrinking)	−84.99% (below 0%: shrinking)	32.57%	0.00%	Compare
Median of peers	$28.9M	—	—	−8.64%	—	−5.79%	64.63%	(4.82%)

All 86 Drug Manufacturers Specialty & Generic stocks →

Rockwell Medical, Inc. (RMTI) key facts

Concern: Rockwell Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $69.3 million, down 31.8% from fiscal 2024.
Rockwell Medical, Inc. (RMTI) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, RMTI traded at $7.43, a market capitalization of $32.2 million.
Return on equity was −15.3% and debt-to-equity 0.26.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −7.44 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.